

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 3, 2003, 18:26:51 ; Search time 7218 Seconds
(without alignments)
11305.662 Million cell updates/sec

Title: US-10-023-782A-3

Perfect score: 2804

Sequence: 1 tcgcagagccgcgcgtgcgt.....gaaaaaaaaaaaaaaaaa 2804

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 841850

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenBank1:
1: gb_da:*
2: gb_htg:*
3: gb_in:*
4: gb_cm:*
5: gb_ov:*
6: gb_pac:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vl:*
15: em_da:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pac:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vl:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htg_mus:*
34: em_htg_dln:*
35: em_htg_rtd:*
36: em_htg_mam:*
37: em_htg_vrt:*
38: em_sy:*
39: em_htgo_hum:*
40: em_htgo_mus:*
41: em_htgo_other:*

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
c 1	30.4	1.1	49	6	AX099434
2	30	1.1	45	6	AX287571
3	30	1.1	45	6	AX287575
4	29.2	1.0	43	6	AX287598
5	29.2	1.0	50	6	AX261361
6	29.2	1.0	50	6	136502
7	29	1.0	46	6	AX287578
8	29	1.0	46	6	AX287582
9	28.8	1.0	45	6	E50989
c 10	28.4	1.0	40	6	A48799
11	28.4	1.0	46	6	AX287579
12	28.4	1.0	46	6	AX287583
13	28	1.0	37	6	AX106972
c 14	28	1.0	37	6	I29931
15	27.8	1.0	43	6	AX443022
16	27.8	1.0	43	6	AX459616
17	27.8	1.0	44	6	AX206861
c 18	27.6	1.0	44	6	AR038858
c 19	27.6	1.0	49	11	G73668
20	27.4	1.0	38	6	E50766
21	27.4	1.0	49	3	DD063607
22	27.4	1.0	50	6	I23510
23	27.4	1.0	50	6	I28359
24	27.4	1.0	50	6	I28514
25	27.4	1.0	50	6	I41125
26	27.4	1.0	50	6	I49056
27	27.4	1.0	50	6	I70295
28	27.4	1.0	50	6	I90068
29	27.2	1.0	33	6	BD011883
30	27.2	1.0	33	23	BD004363
31	27.2	1.0	42	6	I32405
32	27.2	1.0	47	6	AX458031
c 33	27.2	1.0	48	6	AX166869
c 34	26.8	1.0	44	6	I29927
35	26.6	0.9	43	6	AX395321
36	26.6	0.9	43	6	AX484406
37	26.2	0.9	46	6	AX287577
38	26.2	0.9	46	6	AX287581
39	26.2	0.9	49	11	G73668
40	26	0.9	34	6	A63578
41	26	0.9	45	6	AX287570
42	26	0.9	45	6	AX287574
43	25.8	0.9	48	6	AR020989
44	25.8	0.9	48	6	AR043404
45	25.8	0.9	48	6	AR062319

ALIGNMENTS

RESULT 1
AX099434/c 49 bp DNA linear PAT 02-APR-2001
LOCUS AX099434
DEFINITION Sequence 74 from Patent WO0119988.
ACCESSION AX099434
VERSION AX099434.1 GI:13538544
KEYWORDS human.
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 49)
AUTHORS Jacobs,K., McCoy,J.M., Lavallie,E.R., Collins-Racie,L.A., Evans,C.,
Merberg,D., Treacy,M., Bowman,M.R., Spaulding,V., and Agostino,M.J.
TITLE Secreted proteins and polynucleotides encoding them

Pred. No. is the number of results predicted by chance to have a

JOURNAL	Patent: WO 0119988-A 74 22-MAR-2001;
Genetics Institute, Inc. (US)	
FEATURES	Location/Qualifiers
source	1..49
	/organism="Homo sapiens"
	/db_xref="taxon:9606"
misc_feature	1..49
	/note="n = A,T,C or G"
BASE COUNT	44 a 0 c 1 g 3 t 1 others
ORIGIN	
Query Match	1.1%; Score 30.4; DB 6; Length 49;
Best Local Similarity	75.5%; Pred. No. 1.6e+05;
Matches	37; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
Oy	2151 TTGATTTTTCCTCCCTTTTTTTTTTTTTTTTAACCTTGAAACTT 2199
Db	49 TTTTCTTTTTCCTTTAATTTTTTTTTTTTTTTTTTTTAAATT 1
RESULT 2	
LOCUS	AX287571 45 bp DNA linear PAT 21-NOV-2001
DEFINITION	Sequence 14 from Patent W00177390.
ACCSSION	AX287571
VERSION	AX287571.1 GI:17049337
KEYWORDS	.
SOURCE	. synthetic construct.
ORGANISM	. synthetic construct.
REFERENCE	1 artificial sequences.
AUTHORS	abarz A.P.
TITLE	Process for allele discrimination utilizing primer extension
JOURNAL	Patent: WO 0177390-A 14 18-OCT-2001;
	Molecular Staging, Inc. (US)
FEATURES	location/Qualifiers
source	1..45
	/organism="synthetic construct"
	/db_xref="taxon:32630"
	/note="P1 primer for use in allele discrimination"
BASE COUNT	1 a 6 c 0 g 38 t
ORIGIN	
Query Match	1.1%; Score 30; DB 6; Length 45;
Best Local Similarity	86.8%; Pred. No. 1.9e+05;
Matches	33; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
Oy	2155 TTTTTCCTCCTTTTTTTTTTTTTTTTAACTTT 2192
Db	4 TTTTCTTTTTCCTTTTTTTTTTTTTTTTCAACTT 41
RESULT 3	
LOCUS	AX287575 45 bp DNA linear PAT 21-NOV-2001
DEFINITION	Sequence 18 from Patent W00177390.
ACCSSION	AX287575
VERSION	AX287575.1 GI:17049341
KEYWORDS	.
SOURCE	. synthetic construct.
ORGANISM	. synthetic construct.
REFERENCE	1 artificial sequences.
AUTHORS	abarz A.P.
TITLE	Process for allele discrimination utilizing primer extension
JOURNAL	Patent: WO 0177390-A 18 18-OCT-2001;
	Molecular Staging, Inc. (US)
FEATURES	location/Qualifiers
source	1..45
	/organism="synthetic construct"
	/db_xref="taxon:32630"
	/note="P1 primer for use in allele discrimination"
BASE COUNT	2 a 5 c 0 g 38 t

[illegible]

REFERENCE	abarz A.P.									
AUTHORS	Process for allele discrimination utilizing primer extension									
TITLE	Patent: WO 0177390-A 25 18-OCT-2001;									
JOURNAL	Molecular Staging, Inc. (US)									
FEATURES	Location/Qualifiers									
source	1..46									
	/organism="synthetic construct"									
	/db_xref="taxon:32630"									
	/note="P1 primer for use in allele discrimination"									
BASE COUNT	2 a 4 c 0 g 40 t									
ORIGIN										
Query Match	1.0%: Score 29; DB 6; Length 46;									
Best Local Similarity	86.5%: Pred. No. 2.9e+05;									
Matches 32; Conservative	0; Mismatches 5; Indels 0; Gaps 0;									
Qy 2155	TTTTTTTCCTTTTTTTTTTTTTTTTAACTT 2191									
Db 1	TTTTTTTTTTTTTTTTTTTTTTTTTTTCATT 37									
RESULT 9	45 bp DNA linear PAT 31-JAN-2002									
E50989/c										
LOCUS	E50989									
DEFINITION	Method for measuring nucleic acid and kit therefor.									
ACCESSION	E50989									
VERSION	E50989.1 GI:18622166									
KEYWORDS	JP 2000300267-A/3.									
SOURCE	JP 2000300267-A/3.									
ORGANISM	synthetic construct.									
REFERENCE	artificial sequences.									
AUTHORS	1 (bases 1 to 45)									
JOURNAL	Fujimura,K.									
COMMENT	Method for measuring nucleic acid and kit therefor									
	Patent: JP 2000300267-A 3 31-OCT-2000;									
	GIUTSU KENKYU KUMAI IRYO FUKUSHI KIKI KENKYUSHO									
	OS Artificial Sequence									
	PN JP 2000300267-A/3									
	PD 31-OCT-2000									
	PF 21-APR-1999 JP 1999113165									
	PR									
	PI KATSUYA FUJIMURA									
	PC C12N15/09,C12Q1/68,C12N15/00									
	CC									
	CF									
	FH Key Location/Qualifiers									
	FT source 1..45									
FEATURES	Location/Qualifiers									
source	1..45									
	/organism="synthetic construct"									
	/db_xref="taxon:32630"									
BASE COUNT	40 a 4 c 1 g 0 t									
ORIGIN										
Query Match	1.0%: Score 28.8; DB 6; Length 45;									
Best Local Similarity	82.5%: Pred. No. 3.1e+05;									
Matches 33; Conservative	0; Mismatches 7; Indels 0; Gaps 0;									
Qy 2153	GATTTTTCCTTTTTTTTTTTTAACTT 2192									
Db 41	GTTTTTTTTTTTTTTTTTTTTTTTTTTT 2									
RESULT 10	40 bp DNA linear PAT 07-MAR-1997									
LOCUS	A48799/c									
DEFINITION	Sequence 6 from Patent WO9605528.									
ACCESSION	A48799									
VERSION	A48799.1 GI:2302466									
KEYWORDS										
ORGANISM	unidentified.									

REFERENCE	1 (bases 1 to 40)	unclassified.
AUTHORS	Petrík, J., Allain, J. and Pearson, G. J.	
TITLE	OLIGONUCLEOTIDES AND THEIR USE	
JOURNAL	Patent: WO 9603528-A 6 08-FEB-1996; LYNXVALE LTD (GB)	
COMMENT	Other publication AU 318395 960222.	
FEATURES	Location/Qualifiers	
SOURCE	1..40	
	/organism="unidentified"	
	/db_xref="taxon:32644"	
BASE COUNT	40 a 0 c 0 g 0 t	
ORIGIN		
Query Match	1.0%; Score 28.4; DB 6;	Length 40;
Best Local Similarity	84.2%; Pred. No. 3.7e+05;	
Matches 32; Conservative	0; Mismatches 6;	Indels 0; Gaps 0;
QY 2155	TTTTTTCCTTTT	TTTTTTCCTTTT
Db 40	TTTTTTCCTTTT	TTTTTTCCTTTT
RESULT 11		
AX287579		
LOCUS	AX287579	46 bp DNA
DEFINITION	Sequence 22 from Patent WO0177390.	linear PAT 21-NOV-2001
ACCESSION	AX287579	
VERSION	AX287579.1 GI:17049345	
KEYWORDS		
SOURCE	synthetic construct.	
ORGANISM	artificial sequence.	
REFERENCE	1	
AUTHORS	abarz A,P.	
TITLE	Process for allele discrimination utilizing primer extension	
JOURNAL	Patent: WO 0177390-A 22 18-OCT-2001;	
FEATURES	Molecular Staging, Inc. (US)	
SOURCE	Location/Qualifiers	
	1..46	
	/organism="synthetic construct"	
	/db_xref="taxon:32630"	
	/note="PI primer for use in allele discrimination"	
BASE COUNT	2 a 3 c 0 g 41 t	
ORIGIN		
Query Match	1.0%; Score 28.4; DB 6;	Length 46;
Best Local Similarity	84.2%; Pred. No. 3.7e+05;	
Matches 32; Conservative	0; Mismatches 6;	Indels 0; Gaps 0;
QY 2155	TTTTTTCCTTTT	TTTTTTCCTTTT
Db 4	TTTTTTCCTTTT	TTTTTTCCTTTT
RESULT 12		
AX287583		
LOCUS	AX287583	46 bp DNA
DEFINITION	Sequence 26 from Patent WO0177390.	linear PAT 21-NOV-2001
ACCESSION	AX287583	
VERSION	AX287583.1 GI:17049349	
KEYWORDS		
SOURCE	synthetic construct.	
ORGANISM	artificial sequence.	
REFERENCE	1	
AUTHORS	abarz A,P.	
TITLE	Process for allele discrimination utilizing primer extension	
JOURNAL	Patent: WO 0177390-A 26 18-OCT-2001;	
FEATURES	Molecular Staging, Inc. (US)	
SOURCE	Location/Qualifiers	
	1..46	
	/organism="synthetic construct"	

[illegible]

PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226686.
PR 23-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227189.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229511.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231411.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 12-SEP-2000; 2000US-0232081.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234224.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.

PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244517.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 11-DEC-2000; 2000US-0251990.
PR 05-JAN-2001; 2001US-0259678.

(HUMA-) HUMAN GENOME SCI INC.
PI Rosen CA, Barash SC, Ruben SM;
XX WPI; 2001-465570/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
XX used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 10177; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
SQ Sequence 47 BP; 36 A; 4 C; 2 G; 5 T; 0 other;

Query Match

1.1%; Score 31.4; DB 22; Length 47;

Best Local Similarity 85.4%; Pred. No. 2.1e+03;
Matches 35; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

ID	Sequence	Score	DB	Length	Matches	Conservative	Mismatches	Indels	Gaps
RESULT 2									
AL28562/C									
AL28562	standard; DNA; 50 BP.								
AL28562;									
24-JAN-2002	(first entry)								
XX									
DT									
XX									
DE	Human SNP oligonucleotide #1770.								
XX									
KW	Immunosuppressive; immunostimulatory; antiinflammatory; cyostatic;								
KW	neuroprotective; antimicrobial; gene therapy; vaccine; amylase; cancer;								
KW	amyloid protein; angiotensin; apoptosis related protein; cadherin;								
KW	cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;								
KW	complement related protein; cytochrome; kinesin; cytokine; interferon;								
KW	interleukin; G-protein coupled receptor; thioesterase; inflammation;								
KW	multifactorial disease; autoimmune disease; infection;								
KW	nervous system disease; ss.								
XX									
OS	Homo sapiens.								
PN									
XX									
PN	W0200147944-A2.								
PD									
XX	05-JUL-2001.								
XX									
PF	28-DEC-2000; 2000WO-US35498.								
XX									
PR	28-DEC-1999; 99US-0173419.								
XX									
PR	27-DEC-2000; 2000US-0173419.								
XX									
PA	(CURA-) CURAGEN CORP.								
XX									
PI	Shinkets RA, Leach M;								
XX									
DR	WPI; 2001-465210/50.								
XX									
PT	Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases,								
PT	oncogenes and histones, useful for diagnosing and treating, e.g.								
PT	cancer, autoimmune diseases and infections -								
XX									
PS	Claim 1; Page 1886; 4143pp; English.								
XX									
CC	The present invention relates to oligonucleotides encoding polymorphic								
CC	variants of proteins related to amylases, amyloid proteins, angiotensin,								
CC	apoptosis related proteins, cadherin, cyclin, polymerase, oncogenes,								
CC	histones, kinases, colony stimulating factors, complement related								
CC	proteins, cytochromes, kinesins, cytokines, interferons, interleukins,								
CC	G-protein coupled receptors and thioesterases. The present sequence is								
CC	one such oligonucleotide. The oligonucleotides and the peptides encoded								
CC	by them may be used in the prevention, diagnosis and treatment of								
CC	diseases associated with inappropriate expression of the proteins listed								
CC	above. Disorders that may be prevented, diagnosed and/or treated include								
CC	multifactorial diseases with a genetic component, such as autoimmune								
CC	diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes,								
CC	systemic lupus erythematosus and Grave's disease), inflammation, cancer								
CC	(e.g. cancers of the bladder, brain, breast, colon and kidney, cancer								
CC	leukemia), diseases of the nervous system and an infection of pathogenic								
CC	organisms.								
XX									
XX									
Sequence	50 BP; 37 A; 9 C; 1 G; 3 T; 0 other;								
Query Match	1.1%; Score 31.4; DB 22; Length 50;								
Best Local Similarity	77.6%; Pred. No. 2.1e+03;								
Matches 38; Conservative	0; Mismatches 11; Indels 0; Gaps 0;								

```
Oy      2145 TGCTGATGATTTTTTTCCTCCTTTTTTTTTTTTTTTAACTTGG 2193
          ||||| ||||| | ||||||||| ||||| |
Db      49 TGGTGTTTTTTTTTGTGTGCTTTTTTTTTTTTAACCTGG 1
```

RESULT	3
AA0704081	
ID	AA0704081 standard; DNA; 48 BP.
XX	
AC	AA0704081;
XX	
DT	16-MAY-1996 (first entry)
XX	
DE	Trypsin inhibitory protein cDNA antisense primer-1.
XX	
KW	Trypsin; inhibitor; human T98G cells; pancreatitis; shock; DIC;
KW	multiple organ failure; disseminated intravascular coagulation; ss
XX	
OS	Synthetic.
XX	
PN	JP07242700-A.
XX	
PD	19-SEP-1995.
XX	
PF	04-MAR-1994; 94JP-0059906.
XX	
PR	04-MAR-1994; 94JP-0059906.
XX	
PA	(MOCH) MOCHIDA PHARM CO LTD.
XX	
BR	WPI; 1995-355285/46.

PT	Polypeptide having trypsin inhibitory activity - for the treatment
PT	of pancreatitis, shock, multi-organ failure, etc.
PS	Example 7; Page 15; 25pp; Japanese.
XX	
XX	A polypeptide having trypsin inhibitory activity, mol.wt. 22-28 kD
CC	or 17-23 kD (as determined by SDS-PAGE under reducing or non-
CC	reducing conditions, respectively) and an N-terminal sequence as in
CC	CAAR/9913 is claimed. The polypeptide was isolated from human T98G
CC	cells and is useful for treating pancreatitis, shock, multiple
CC	organ failure and disseminated intravascular coagulation. The
CC	present sequence is that of an antisense primer used for cloning
CC	T98G cDNA coding for the full-length polypeptide.
XX	
XX	
XX	Sequence 48 BP; 2 A; 1 C; 1 G; 44 T; 0 other;
XX	

[illegible]

[illegible]

PI	Jacobs K,	McCoY JM,	LaVallie ER,	Collins-Racie LA,	Evans C;
PI	Medberg D,	Treacy M,	Bowman MR,	Spaulding V,	Agostino MJ;
DR	WPI; 2001-244801/25.				
XX					
PT	Isolated nucleic acid encoding polypeptides, useful for modulating				
PT	e.g. cytokine and cell proliferation/differentiation activity, the				
PT	immune system and hematopoiesis regulating activity -				
XX					
PS	Disclosure; Page 429; 557pp; English.				
XX					
CC	Human cDNA clones represented in AAF98374 - AAF98489 encode secreted				
CC	proteins AAB90667 - AAB90750. The cDNA clones are isolated from various				
CC	tissue types, and may be used in the prevention, treatment and diagnosis				
CC	of diseases associated with inappropriate protein expression. The				
CC	polypeptides and nucleic acids may be used as nutrients or to modulate				
CC	cytokine and cell proliferation/differentiation activity and may also be				
CC	involved in modulation of the immune system. The cDNA sequences,				
CC	proteins, their agonists and/or antagonists exhibit haematopoiesis				
CC	regulating activity; tissue growth activity; activin/inhibin activity;				
CC	chemotactic/chemokine activity; hemostatic and thrombolytic				
CC	activity; receptor/ligand activity; anti-inflammatory activity;				
CC	haematopoiesis activity; cachectin/tumour suppressor activity; and/or				
CC	tumour inhibition activity. Included in the invention are probes				
CC	represented in AAF98490 - AAF98572 which are specific for the cDNA clones				
CC	encoding the secreted proteins.				
XX					
SQ	Sequence 49 BP; 44 A; 0 C; 1 G; 3 T; 1 other;				
Query Match	1.1%;	Score 30.4;	DB 22;	Length 49;	
Best Local Similarity	75.5%;	Pred. No. 3.4e+03;			
Matches 37;	Conservative 0;	Mismatches 12;	Indels 0;	Gaps 0	
OY	2151	TTGATTTTTTCTCCCTTTTTTTTTTTTTTTTTTTTAACTTGAAAGCT	2199		
DB	49	TTTTTTTTTTCTTTATTTTTTTTTTTTTTTTTTTTTTTTATTT	1		
RESULT 6					
AAAS95724					
AAAS95724	standard; DNA; 45 BP.				
XX					
AC	AAAS95724;				
XX					
DT	14-FEB-2002 (first entry)				
XX					
DE	Allele discrimination P1 primer #8.				
XX					
KW	Rolling circle amplification; single nucleotide polymorphism; anaemia;				
KW	exonuclease deficient DNA polymerase; amplification target circle; RCA;				
KW	Parkinson's disease; polycystic kidney disease; Tay-Sachs disease; ss;				
KW	Huntington's disease; sickle cell anaemia; haemophilia; cystic fibrosis;				
KW	diabetes; obesity; cancer; head; neck; skin; brain; oesophagus; stomach;				
KW	lung; breast; colon; ovary; testis; prostate; leukaemia; lymphoma;				
KW	melanoma; PCR primer; sequencing primer; probe.				
XX					
OS	Homo sapiens.				
XX					
FN	WO200177390-A2.				
XX					
PD	18-OCT-2001.				
XX					
PF	05-APR-2001; 2001WO-US11151.				
XX					
PR	05-APR-2000; 2000US-194843P.				
XX					
PA	(MOLE-) MOLECULAR STAGING INC.				
PI	Abazua P;				
XX					
DR	WPI; 2002-049157/06.				
XX					
PT	Detecting single nucleotide polymorphism involves amplifying target				

PT sequences using small primer probe that matches or mismatches to target
PT sequence and extending primer probe which is then detected -
XX
PS Claim 15, Page 41, 67pp; English.
XX
CC The invention relates to detecting single nucleotide polymorphisms by
CC contacting an allele-specific oligonucleotide primer (P1) with a target
CC polynucleotide to form a hybridisation complex, where the target sequence
CC is complementary to P1 at one end but the terminal nucleotide and the
CC third nucleotide from the terminal at the other end of P1 may not be
CC complementary. The complex is then contacted with an exonuclease
CC deficient DNA polymerase enzyme under conditions that promote extension
CC of P1 with the target DNA as the template, thereby forming an extended
CC segment of P1. Oligonucleotide probes hybridising to one or more target
CC polynucleotides distinguish between matched and mismatched 3' ends, hence
CC the absence of sequence amplification indicates the presence of a single
CC nucleotide mismatch. Primer sequences complementary to a sequence on an
CC amplification target circle can be used in rolling circle amplification
CC (RCA). The method is useful for diagnosing a disease caused by, induced
CC by or related to a mutation in at least one gene, such as Parkinson's
CC disease, sickle cell anaemia, haemophilia, cystic fibrosis, diabetes,
CC obesity, cancers of the head, neck, skin, brain, oesophagus, stomach,
CC lung, breast, colon, ovary, testis or prostate, leukaemia, lymphoma and
CC melanoma. Sequences AAS95711-AAS95745 represent primers, targets and
CC fluorescence decorators used in the detection of RCA products.
XX
SQ Sequence 45 BP; 1 A; 6 C; 0 G; 38 T; 0 other;

Query Match 1.1%; Score 30; DB 24; Length 45;
Best Local Similarity 86.8%; Pred. No. 4e+03;
Matches 33; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2155 TTTTTCCTCCTTTTCTTTTCTTTTCTTTTACTTT 2192
Db 4 TTTTTCCTCCTTTTCTTTTCTTTTCTTTTACTTT 41

RESULT 7
AAS95728
ID AAS95728 standard; DNA; 45 BP.
XX
AC AAS95728;
XX
DT 14-FEB-2002 (first entry)
XX
DE Allele discrimination P1 primer #12.
XX
KW Rolling circle amplification; single nucleotide polymorphism; anaemia;
KW exonuclease deficient DNA polymerase; amplification target circle; RCA;
KW Parkinson's disease; polycystic kidney disease; Tay-Sachs disease; ss;
KW Huntington disease; sickle cell anaemia; haemophilia; cystic fibrosis;
KW diabetes; obesity; cancer; head; neck; skin; brain; oesophagus; stomach;
KW lung; breast; colon; ovary; testis; prostate; leukaemia; lymphoma;
KW melanoma; PCR primer; sequencing primer; probe.
XX
OS Homo sapiens.
XX
PN WO200177390-A2.
XX
PD 18-OCT-2001.
XX
PF 05-APR-2001; 2001WO-US11151.
XX
PR 05-APR-2000; 2000US-194843P.
XX
PA (MOLE-) MOLECULAR STAGING INC.
XX
PI Abarzua P;
XX
DR WPI; 2002-049157/06.
XX
PT Detecting single nucleotide polymorphism involves amplifying target

PT sequences using small primer probe that matches or mismatches to target
PT sequence and extending primer probe which is then detected -
XX
PS Claim 15, Page 41, 67pp; English.
XX
CC The invention relates to detecting single nucleotide polymorphisms by
CC contacting an allele-specific oligonucleotide primer (P1) with a target
CC polynucleotide to form a hybridisation complex, where the target sequence
CC is complementary to P1 at one end but the terminal nucleotide and the
CC third nucleotide from the terminal at the other end of P1 may not be
CC complementary. The complex is then contacted with an exonuclease
CC deficient DNA polymerase enzyme under conditions that promote extension
CC of P1 with the target DNA as the template, thereby forming an extended
CC segment of P1. Oligonucleotide probes hybridising to one or more target
CC polynucleotides distinguish between matched and mismatched 3' ends, hence
CC the absence of sequence amplification indicates the presence of a single
CC nucleotide mismatch. Primer sequences complementary to a sequence on an
CC amplification target circle can be used in rolling circle amplification
CC (RCA). The method is useful for diagnosing a disease caused by, induced
CC by or related to a mutation in at least one gene, such as Parkinson's
CC disease, sickle cell anaemia, haemophilia, cystic fibrosis, diabetes,
CC obesity, cancers of the head, neck, skin, brain, oesophagus, stomach,
CC lung, breast, colon, ovary, testis or prostate, leukaemia, lymphoma and
CC melanoma. Sequences AAS95711-AAS95745 represent primers, targets and
CC fluorescence decorators used in the detection of RCA products.
XX
SQ Sequence 45 BP; 2 A; 5 C; 0 G; 38 T; 0 other;

Query Match 1.1%; Score 30; DB 24; Length 45;
Best Local Similarity 86.8%; Pred. No. 4e+03;
Matches 33; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2155 TTTTTCCTCCTTTTCTTTTCTTTTCTTTTACTTT 2192
Db 4 TTTTTCCTCCTTTTCTTTTCTTTTCTTTTACTTT 41

RESULT 8
ABK30194/C
ID ABK30194 standard; DNA; 50 BP.
XX
AC ABK30194;
XX
DT 23-APR-2002 (first entry)
XX
DE CYP2D6 gene polymorphism detection primer #33.
XX
KW Human; CYP2D6; primer; single nucleotide polymorphism detection; SNP;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200196604-A2.
XX
PD 20-DEC-2001.
XX
PF 11-JUN-2001; 2001WO-US18912.
XX
PR 12-JUN-2000; 2000US-210988P.
XX
PA (GENI-) GENICON SCI CORP.
XX
PI Bee G, Kohne DE, Korb L, Peterson T, Yguerabide J;
XX
DR WPI; 2002-130745/17.
XX
PT Determining the presence of a CYP2D6 target sequence in a DNA sample
PT containing CYP2D6 nucleic acid, for detecting mutations or
PT polymorphisms, comprises detecting the scattered light from a particle
PT bound to the target sequence -
XX

XX	PD		23-OCT-1997.	
XX	PF	14-APR-1997;	97MO-US06139.	
XX	PR	18-APR-1996;	96US-0634325.	
XX	PA	(GEMY) GENETICS INST INC.		
XX	PI	Jacobs K, Lavallie ER, McCoy JM, Merberg D, Racile IA;		
XX	PI	Spaulding V;		
XX	DR	WPI; 1997-526460/48.		
XX	PT	New secreted proteins encoded clones present in ATCC 98026 -		
XX	PT	possibly having cytokine, cell proliferation/differentiation		
XX	PT	regulating, immunomodulating and many other activities		
XX	PS	Disclosure; Page 86; 139p; English.		
XX	XX	The present sequence encodes a portion of a novel human secreted protein		
XX	CC	deposited under accession number ATCC 98026. The secreted protein can be		
XX	CC	used to determine biological activity, to raise antibodies, as tissue		
XX	CC	markers, to isolate cognate ligands or receptors, to identify agents		
XX	CC	that modulate their interactions and as nutritional supplements. It may		
XX	CC	also have a very wide range of biological activities although no		
XX	CC	evidence for any is provided in the specification. Typical of these are		
XX	CC	cytokine, cell proliferation/differentiation modulating activity or		
XX	CC	induction of other cytokines; immunostimulating/immunosuppressant		
XX	CC	activities (e.g. for treating human immunodeficiency virus infection,		
XX	CC	cancer, autoimmune diseases and allergy); regulation of haematopoiesis		
XX	CC	(e.g. for treating anaemia or as adjunct to chemotherapy); stimulation		
XX	CC	of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for		
XX	CC	treating wounds, periodontal disease, neurological diseases stroke,		
XX	CC	fibrosis); inhibition or stimulation of follicle stimulating hormone		
XX	CC	(for control of fertility); chemotactic and chemokinetic activities		
XX	CC	(e.g. for treating infections, tumours); haemostatic or thrombolytic		
XX	CC	activity (e.g. for treating hemophilia); cardiac infarction etc.);		
XX	CC	anti-inflammatory activity (e.g. for treating septic shock, Crohn's		
XX	CC	disease); as antimicrobials; for treating psoriasis or other		
XX	CC	hyperproliferative disease; for regulation of metabolism, behaviour, and		
XX	CC	many others. Also contemplated is the use of the corresponding nucleic		
XX	CC	acid in gene therapy procedures.		
XX	SQ	Sequence 49 BP; 40 A; 2 C; 6 G; 1 T; 0 other;		
XX	Query Match	1.0%; Score 29.2; DB 18; Length 49;		
XX	Best Local Similarity	81.0%; Pred. No. 6.2e+03;		
XX	Matches 34; Conservative	0; Mismatches 8; Indels 0; Gaps 0;		
XX	OY	2151 TTGATTTTTCGCCCTTTTTTTTTTTTTTTTAACATT 2192		
XX	Db	48 TCGAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT 7		
XX	RESULT 14			
XX	ID	AAQ66922/c		
XX	AC	AAQ66922 standard; DNA; 50 BP.		
XX	AAQ66922;			
XX	DT	24-JAN-1995 (first entry)		
XX	DE	Poly-da 50mer probe target sequence.		
XX	KM	Target sequence; binding ability; hairpin forming; probes;		
XX	KW	Imperfect hairpin; acceptor label moiety; donor moiety label;		
XX	KM	fluorescence; fluorophores; specificity; base pair mismatches;		
XX	KS	competitive arms; ss.		
XX	OS	Synthetic.		
XX	SH	Key Location/Qualifiers		

FT	misc_binding	2..26
FT		/+tag= a
FT		/note= "Target sequence for probe binding"
XX		
XX	EP601889-A.	
XX		
PD	15-JUN-1994.	
XX		
PF	10-DEC-1993;	93BP-0310007.
XX		
PR	10-DEC-1992;	92US-0990298.
XX		
PA	(MAIN-) MAINE MEDICAL CENT RES INST.	
PB		
PI	Bagwell BC;	
DR	WPI; 1994-185245/23.	
PT	Nucleic acid probe for use in DNA or RNA hybridisation assays -	
PT	comprises a nucleotide sequence which is capable of forming one	
XX	or more hairpins	
XX		
PS	Disclosure; Fig 2; 25pp; English.	
XX		
CC	This sequence represents a target sequence which was used to demonstrate	
CC	the binding ability of the hairpin forming probes of the invention. The	
CC	probes comprise a segment complementary to the target nucleotide and are	
CC	capable of forming at least 1 imperfect hairpin. The probes contain at	
CC	least one acceptor label moiety and at least one donor moiety label	
CC	which are covalently attached to the nucleotide sequence so that when	
CC	the hairpins are formed the moieties are in close proximity to allow	
CC	resonance energy transfer between them. This causes a reduction in the	
CC	fluorescence of the two fluorophores. The target sequence contains at	
CC	least 22 nucleotides to ensure specificity and avidity of the probe-	
CC	target hybridisation. The hairpins formed are imperfect hairpins and	
CC	the intentional base pair mismatches are introduced into the competitive	
CC	arms such that the specificity sequence will favour binding to the	
CC	target sequence. Therefore when the probe interacts with the target	
CC	sequence the competitive arm is displaced, increasing the distance	
CC	between the fluorophores, resulting in a change in fluorescent emission.	
XX		
SQ	Sequence 50 BP; 50 A; 0 C; 0 G; 0 T; 0 other;	
	Query Match	1.0%; Score 29.2; DB 15; Length 50;
	Best Local Similarity	81.0%; Pred. No. 6.2e+03;
	Matches 34; Conservative 0; Mismatches 8; Indels 0; Gaps 0;	
QY	2151 TTGATTTTTCCTCTTTTTCCTTTTTTTTACATT 2192	
DB	50 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT 9	
RESULT 15		
AAAF60897/c		
ID	AAAF60897 standard; DNA; 50 BP.	
XX		
AC	AAAF60897;	
XX		
DT	15-MAY-2001 (first entry)	
XX		
DE	Conjugate forming oligonucleotide ON6 SEQ ID 6.	
XX		
KM	Transport; membrane; cytosolic; vinucide; vasotropic; dermatological;	
KW	antisociatic; antistigmatic; gene therapy; tumor cell; antisense;	
KW	tumor therapy; drug; phosphodiester linkage; ss.	
XX		
OS	Unidentified.	
XX		
XX	DEL19935302-A1.	
PN		
XX	08-FEB-2001.	
XD		
XX	28-JUL-1999; 99DE-1035302.	
XF		


```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA (genomic)
; US-08-113-646A-44

```

```

QY      2151 TTGATTTTTCCTCCCTTTTTTTTTTTTTTTTTT 2186
          |||||
Db       37 TTTTGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 2

```

RESULT 8
US-08-664-596B-9/c
; Sequence 9, Application US/08664596B
; Patent No. 5807703

1 APPLICANT: Jacobs, Kenneth
 2 APPLICANT: McCoy, John
 3 APPLICANT: Lavallie, Edward
 4 APPLICANT: Racie, Lisa
 5 APPLICANT: Merberg, David
 6 APPLICANT: Treacy, Maurice
 7 APPLICANT: Evans, Cheryl
 8 APPLICANT: Spaulding, Vikki
 9 APPLICANT: Bowman, Michael
 10 TITLE OF INVENTION: SECRETED PROTEINS AND POLYNUCLEOTIDES
 11 TITLE OF INVENTION: ENCODING THEM
 12 NUMBER OF SEQUENCES: 37

ADDRESS: Genetics Institute, Inc.
STREET: 87 Cambridgepark Drive
CITY: Cambridge
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02140
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/664,536B

```

? CLASSIFICATION: 514
? ATTORNEY/AGENT INFORMATION:
? NAME: Brown, Scott A.
? REGISTRATION NUMBER: 32,722
? TELECOMMUNICATION INFORMATION
? TELEPHONE: (617) 498-8224
? TELEFAX: (617) 876-5851
? INFORMATION FOR SEQ ID NO: 9:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 44 base pairs
? TYPE: nucleic acid
? STRANDEDNESS: double
? TOPOLOGY: linear
? MOLECULE TYPE: CDNA
? OS=08-664-596B-9

```

Query Match	1.0%;	Score 27.6;	DB 1;	Length 44;
Best Local Similarity	78.6%;	Pred. No. 1.1e+03;		
Matches 33; Conservative	0;	Mismatches 9;	Indels 0;	Gaps 0

OY	2151	TTCATTTTCTCCTTTTTTTTTTTTTTTAACTTT	2192
D6	44	TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	3

RESULT 9

US-08-233-609-5
; Sequence 5, Application US/08233609
; Patent No. 5534615

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPLETED PENDANT FORM.

COMPUTER READABLE FORM:
MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: patin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US-08/233,609
FILING DATE: 25-APR-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILED DATE: _____
ATTORNEY/AGENT INFORMATION: _____
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: 89
TELECOMMUNICATION INFORMATION: _____
TELEPHONE: 415/225-1896
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SED ID NO: 5:
SEQUENCE CHARACTERISTICS: _____

;
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ;
 US-08-233-609-5

Query Match	1.0%;	Score 27.4;	DB 1;	Length 50;
Best Local Similarity	75.6%;	Pred. No. 1.3e+03;		
Matches 34; Conservative	0;	Mismatches 11;	Indels 0;	Gaps 0;

```

QY      2142 GCCCTGCTGATTCGATTTTCTCCTTTTTTTTTTTTTTTTTTTTTT 2186
          ||| | | | | | | | | | | | | | | | | | | | | | | |
Db       4   GCGCGAGCTCGAATTCCTTTTTTTTTTTTTTTTTTTTTTTTTTT 48

```

RESULT 10
US-08-444-083-5
; Sequence 5, Application US/08444083

```

? GENERAL INFORMATION:
? APPLICANT: Baker, Joffre
? APPLICANT: Chlen, Kenneth
? APPLICANT: King, Kathleen
? APPLICANT: Penhela, Diane
? APPLICANT: Wood, William
? TITLE OF INVENTION: Cardiac Hypertrophy Factor and Uses Therefor
? NUMBER OF SEQUENCES: 8
? CORRESPONDENCE ADDRESSES:

```

ADDRESS: genentech, inc.
STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA

C-C#1-744-90 20


```

? CURRENT APPLICATION NUMBER: US/09/827,289
? CURRENT FILING DATE: 2001-04-05
? PRIOR APPLICATION NUMBER: U.S. 60/194843
? PRIOR FILING DATE: 2000-04-05
? NUMBER OF SEQ ID NOS: 35
? SOFTWARE: PatentIn Ver. 2.1
? SEQ ID NO 18
? LENGTH: 45
? TYPE: DNA
? ORGANISM: Artificial Sequence
FEATURE:
? OTHER INFORMATION: Description of Artificial Sequence: P1 primer for
? OTHER INFORMATION: use in allele discrimination
US-09-827-289-18

```

	Query Match	1.1%	Score 30	DB 10:	Length 45;
	Best Local Similarity	86.8%;	Pred. No.	1e+03;	
Matches	33; Conservative	0;	Mismatches	5;	Indels 0;
Gaps					
QY	2155 TTTTTCCTCCTTTTTTTTTTTTTTTAAACTTT	2192			
DG	4 TTTTTCCTCCTTTTTTTTTTTCAACCTTT	41			

```

RESULT 3
US-09-815-343-1012
; Sequence 1012' Application US/09815343
; Patient No. US20010055596A1
; GENERAL INFORMATION:
; APPLICANT: Meagher, Madeleine
; APPLICANT: Xu, Jiangchun
; APPLICANT: King, Gordon E.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND
; TITLE OF INVENTION: DIAGNOSIS OF COLON CANCER
; FILE REFERENCE: 210121.504
; CURRENT APPLICATION NUMBER: US/09/815,343
; CURRENT FILING DATE: 2001-03-22
; NUMBER OF SEQ. ID NOS: 1556
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ. ID NO 1012
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Homo sapien
; US-09-815-343-1012

```

[illegible]

```

RESULT 4
US-09-827-289-21
: Sequence 21, Application US/09827289
: Patent No. US20020009716A1
: GENERAL INFORMATION:
: APPLICANT: Abarzua, Patricia
: TITLE OF INVENTION: Process for Allele Discrimination Using Primer
: TITLE OF INVENTION: Extension
: FILE REFERENCE: 469290-55
: CURRENT APPLICATION NUMBER: US/09/827,289
: CURRENT FILING DATE: 2001-04-05
: PRIOR APPLICATION NUMBER: U.S. 60/194843
: PRIOR FILING DATE: 2000-04-05
: NUMBER OF SEQ ID NOS: 35
: SOFTWARE: PatentIn Ver. 2.1
: SEQ ID NO 21
: LENGTH: 46
: TYPE: DNA
: ORGANISM: Artificial Sequence

```

```
;; FEATURE: Description of Artificial Sequence: P1 primer for
;; OTHER INFORMATION: use in allele discrimination
US-09-827-289-21
```

	Query Match	1.0%	Score 29:	DB 10:	Length 46:
	Best Local Similarity	86.5%	Pred. No.	1.7e+03:	
Matches	32;	Conservative	0;	Mismatches	5; Indels 0; Gaps 0;
QY	2155	TTTTTTTCGCTTTTTTTTTTTTTTAACT	2191		
Dd	1	TTTTTTTTTTTTTTTTTTTTTTTCAATT	37		

```

RESULT 5
US-09-827-289-25
: Sequence 25, Application US/09827289
: Patent No. US20020009716a1
GENERAL INFORMATION:
APPLICANT: Abdrizua, Patricia
TITLE OF INVENTION: Process for Allele Discrimination Using Primer
: TITLE OF INVENTION: Extension
FILE REFERENCE: 469290-55
CURRENT APPLICATION NUMBER: US/09/827,289
CURRENT FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: U.S. 60/194843
PRIOR FILING DATE: 2000-04-05
NUMBER OF SEQ ID NOS: 35
SOFTWARE: PatentIn Ver. 2.1
: SEQ ID NO 25
: LENGTH: 46
: TYPE: DNA
: ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: p1 primer
US-09-827-289-25

```

	Query Match	1.0%	Score 29	DB 10:	length 46;
	Best Local Similarity	86.5%	Pred. No.	1.7e+03;	
	Matches 32; Conservative	0;	Mismatches 5;	Indels 0;	Gaps 0;
OY	2155 TTTTTCCTCCTTTTTTTTTTTTTTTAACTT	2191			
Dd	1 TTTTTCCTCCTTTTTTTTTTTTTTTCAATT	37			

```

RESULT 6
US-09-827-289-22
Sequence 22, Application US/09827289
Patent No. US2002009716a1
GENERAL INFORMATION:
APPLICANT: Abarzua, Patricia
TITLE OF INVENTION: Process for Allele Discrimination Using Primer
TITLE OF INVENTION: Extension
FILE REFERENCE: 469290-55
CURRENT APPLICATION NUMBER: US/09/827,289
CURRENT FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: U.S. 60/194843
PRIOR FILING DATE: 2000-04-05
NUMBER OF SEQ ID NOS: 35
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 22
LENGTH: 46
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: p1 primer for
US-09-827-289-22

```

Query Match	1.0%;	Score 28.4;	DB 10;	Length 46;
Best Local Similarity	84.2%;	Pred. No. 2.3e+03;		


```

1 RESULT 14
2 US-09-920-581-9
3
4 ; Sequence 9, Application US/09920581
5 ; Patent No. US20020151073A1
6
7 ; GENERAL INFORMATION:
8 ; APPLICANT: Christensen, Tove
9 ; TITLE OF INVENTION: A Transcription Factor
10 ; FILE REFERENCE: 4484.204-US
11
12 ; CURRENT APPLICATION NUMBER: US/09/920,581
13 ; CURRENT FILING DATE: 2001-08-01
14
15 ; PRIOR APPLICATION NUMBER: 09/197,814
16 ; PRIOR FILING DATE: 1998-11-23
17
18 ; PRIOR APPLICATION NUMBER: PCT/DK97/00305
19 ; PRIOR FILING DATE: 1997-07-07
20
21 ; NUMBER OF SEQ ID NOS: 14
22
23 ; SOFTWARE: FastSeq for Windows Version 3.0
24
25 ; SEQ ID NO 9
26 ; LENGTH: 41
27
28 ; TYPE: DNA
29
30 ; ORGANISM: Artificial Sequence
31
32 ; FEATURE:
33
34 ; OTHER INFORMATION: Primer

```


GenCore version 5.1.4-p5_4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 3, 2003, 19:09:40 ; Search time 3815 Seconds
(without alignments)
11903.577 Million cell updates/sec

Title: US-10-023-782a-3
Perfect score: 2804
Sequence: 1 tcgcagagccgcgcatgctc.....gaaaaaaaaaaaaaaaaa 2804

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues
Total number of hits satisfying chosen parameters: 102860

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estnu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_est1:*
10: gb_est2:*
11: gb_hic:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vrt:*
22: em_gss_fun:*
23: em_gss_mam:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_rtd:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	35.2	1.3	49	9	AI270095 qt63c08.x
2	33.8	1.2	49	9	AA966391 w4f01a1.r
3	33	1.2	49	9	AA116935 m22g01.r
4	32.4	1.2	49	9	AI350847 q11e08.x
5	31.6	1.1	47	2	HSW002907 AI038431 Homo sapi
6	31.4	1.1	50	9	AA120437 m47a11.r

c	7	31.4	1.1	50	9	AA590944 vm25f02.r
c	8	31.2	1.1	48	10	AV950753 AV950753
c	9	31	1.1	46	2	HSM003158 HSM003158
c	10	31	1.1	49	2	HSM001347 HSM001347
c	11	31	1.1	49	9	AI431439 AI431439
c	12	30.8	1.1	45	12	BF582680 BF582680
c	13	30.8	1.1	47	9	AL642997 AL642997
c	14	30.8	1.1	47	10	AW250836 AW250836
c	15	30.8	1.1	49	9	AL048743 AL048743
c	16	30.8	1.1	50	13	BI491716 BI491716
c	17	30.8	1.1	50	14	BQ256372 BQ256372
c	18	30.4	1.1	48	9	AL628936 AL628936
c	19	30.4	1.1	49	9	AA254893 AA254893
c	20	30.4	1.1	50	2	HSM009683 HSM009683
c	21	30.4	1.1	50	14	BQ393428 BQ393428
c	22	30.2	1.1	44	9	AL640163 AL640163
c	23	30.2	1.1	45	10	AW249952 AW249952
c	24	30.2	1.1	46	2	HSM001086 HSM001086
c	25	30.2	1.1	47	2	HSM002960 HSM002960
c	26	30.2	1.1	50	9	AL587874 AL587874
c	27	30	1.1	39	17	TA116F09P TA116F09P
c	28	30	1.1	49	9	AA526728 AA526728
c	29	30	1.1	49	12	BF343486 BF343486
c	30	30	1.1	49	13	BI090256 BI090256
c	31	30	1.1	49	13	BI858831 BI858831
c	32	30	1.1	49	17	AZ587341 AZ587341
c	33	30	1.1	50	2	HSM002946 HSM002946
c	34	30	1.1	50	10	AW333255 AW333255
c	35	30	1.1	50	12	BG256941 BG256941
c	36	30	1.1	50	13	BI493940 BI493940
c	37	30	1.1	50	14	BQ265586 BQ265586
c	38	29.8	1.1	50	9	AA564185 AA564185
c	39	29.8	1.1	50	9	AL641164 AL641164
c	40	29.6	1.1	35	12	BE894682 BE894682
c	41	29.6	1.1	38	17	AZ773771 AZ773771
c	42	29.6	1.1	44	12	BG117508 BG117508
c	43	29.6	1.1	45	9	AL587540 AL587540
c	44	29.6	1.1	45	12	BF525658 BF525658
c	45	29.6	1.1	45	17	AZ467950 AZ467950

ALIGNMENTS

RESULT 1
AI270095 49 bp mRNA linear EST 17-NOV-1998
qt63c08.x1 NCI CGAP_Eso2 Homo sapiens cDNA clone IMAGE:1959950 3',
DEFINITION
mRNA sequence.
ACCESSION
AI270095
VERSION
AI270095.1 GI:3889262
KEYWORDS
EST.
SOURCE
human.
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 49)
AUTHORS
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL
Unpublished (1997)
COMMENT
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-rcmail.nih.gov
Tissue Procurement: Nan Hu, M.D., Ph.D., Mark Roth, M.D., Phillip
Taylor, M.D., Michael R. Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: Life Technologies, Inc.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.bio.lnl.gov/bdip/image/image.html
Seq primer: -40UP from Gldco.
Location/Qualifiers

FEATURES

```

source
    1..49
        /organism="Homo sapiens"
        /db_xref="taxon:9606"
        /clone_image="I939S30"
        /clone_lib="NCI_CGAP_Esc2"
        /tissue_type="squamous cell carcinoma"
        /lab_host="DH10B"
        /note="Organ: esophagus; Vector: pCMV-SPORT6; Site_1: SalII
            ; Site_2: NotI; Cloned unidirectionally. Primer: Oligo
            dT. Average insert size 1.1 kb. Life Technologies catalog
            #: 11502-010"
BASE COUNT      3 a          0 c          2 g         44 t
ORIGIN

Query Match           1.3%; Score 35.2; DB 9; Length 49;
Best Local Similarity   83.3%; Pred. No. 3.6e+05;
Matches 40; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Oy     2151 TTGAATTTTCCTCCTTTTTTTTTTTTTTTTTTAACCTTGAAAGT 2198
       ||| |||||||| | | ||||||||||||| ||| |||||
Db     2 TTTGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAGA GT 49

RESULT 2
AAG66391/c              50 bp mRNA linear EST 31-JUL-1998
LOCUS                     w4f01a1.r1 Aspergillus nidulans 24hr asexual developmental and
DEFINITION                vegetative CDNA lambda zap library Emericella nidulans CDNA clone
                           w4f01a1 5' , mRNA sequence.
ACCESSION                 AAG66391
VERSION                   AAG66391.1 GI:3140473
KEYWORDS                  EST.
SOURCE                    Emricella nidulans.
ORGANISM                  Eukariota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
                           Euryarales; Trichocomaceae; Emericella.
REFERENCE                  1 (bases 1 to 50)
AUTHORS                   Kupfer,D., Gray,J., Hausner,J., Lai,H., Martin,W., Aramayo,R.,
                           Prade,R. and Roe,B.
TITLE                     An Aspergillus nidulans EST Database
JOURNAL                   Unpublished (1998)
COMMENT                   Contact: Bruce A. Roe, University of Oklahoma, broeeou.edu
                           Department of Chemistry and Biochemistry
                           Advanced Center for Genome Technology, University of Oklahoma
                           620 Parrington Oval, Norman, OK 73019, USA
                           Tel: 405 325 4912
                           Fax: 405 325 7762
                           Email: broeeou.edu
                           We anticipate the future release of the cdna clones to the Fungal
                           Genetics Stock Center
                           Seq primer: T3.

FEATURES
Source                      Location/Qualifiers
                                1..50
                                 /organism="Emericella nidulans"
                                 /strain="FGSC A26"
                                 /db_xref="taxon:162425"
                                 /clone="w4f01a1"
                                 /clone_lib="Aspergillus nidulans 24hr asexual
                                     developmentl and vegetative CDNA lambda zap library"
                                 /tissue_type="vegetative mycelia, asexual structures"
                                 /note= "Vector: pluescript SK-, site_1: EcoRI; site_2:
                                     XhoI; 5' end of CDNA cloned into EcoRI site of pluescript
                                     3' end of CDNA cloned into XhoI site of pluescript"
BASE COUNT      42 a          1 c          3 g          4 t
ORIGIN

Query Match           1.2%; Score 33.8; DB 9; Length 50;
Best Local Similarity   84.4%; Pred. No. 5.7e+05;
Matches 38; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Oy     2151 TTGATTTTTTCGCCCTTTTTTTTTTTTTTTTACTTGAAA 2195
       || | ||||||| | | ||||||||||||| ||| |||||
Db     45 TTTTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAACTCGCAA 1

```

LOCUS	AA116935/c	49 bp	mRNA	linear	EST 15-NOV-1996
RESULT 3					
DEFINITION	AA116935	49 bp	mRNA	linear	EST 15-NOV-1996
LOCUS	AA116935/c				
DEFINITION	mm22g01.1 Beddington mouse embryonic region Mus musculus cDNA				
LOCUS	AA116935				
DEFINITION	clone IMAGE:538704 5', mRNA sequence.				
LOCUS	AA116935.1				
DEFINITION	GI:1671951				
LOCUS	EST.				
DEFINITION	house mouse.				
LOCUS	Mus musculus				
DEFINITION	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.				
LOCUS	1 (bases 1 to 49)				
DEFINITION	Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T., Geiselberg,K., Kucaba,T., Lacy,M., Le,M., Martin,D., Morris,M., Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B., Thisinger,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and Waterston,R.				
LOCUS	The WashU-HHMI Mouse EST Project				
DEFINITION	Unpublished (1996)				
LOCUS	Contact: Marra M/Mouse EST Project				
DEFINITION	WashU-HHMI Mouse EST Project				
LOCUS	4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108				
DEFINITION	Tel: 314 286 1800				
LOCUS	Fax: 314 286 1810				
DEFINITION	Email: mouseest@watson.wustl.edu				
LOCUS	This clone is available royalty-free through LINDA; contact the				
DEFINITION	IMAGE Consortium (info@image.lindl.gov) for further information.				
LOCUS	MG1:325640				
DEFINITION	Seq primer: -40m13.ET.				
LOCUS	Location/Qualifiers				
DEFINITION	1..49				
LOCUS	/organism="Mus musculus"				
DEFINITION	/strain="C57BL/6 x DBA"				
LOCUS	/db_xref="taxon:10090"				
DEFINITION	/clone="IMAGE:538704"				
LOCUS	/clone_lib="Beddington mouse embryonic region"				
DEFINITION	/sex="pooled"				
LOCUS	/tissue_type="embryo"				
DEFINITION	/dev_stage="7.5dpc"				
LOCUS	/lab_host="DH12S"				
DEFINITION	/note="Organ: whole embryo; Vector: pCMV-SPOF; Site:1; Salt: Site:2; Note: Cloned unidirectionally. Primer: Oligo dT. Gastrulating embryos were collected at 7.5dpc from C57BL/6 x DBA matings, excluding embryonic that had developed head folds and all extraembryonic tissues. Average insert size: 1.3 kb (range: 0.5 - 3.0 kb). Referenced in Development 121, 2479-2489 (1995)."				
LOCUS	44 a				
DEFINITION	1 c				
LOCUS	0 g				
DEFINITION	4 t				
LOCUS	BASE COUNT				
DEFINITION	44 a				
LOCUS	ORIGIN				
DEFINITION	Query Match				
LOCUS	Best Local Similarity 79.6%, Score 33; DB 9; Length 49;				
DEFINITION	Matches 39; Conservative 0; Mismatches 10; Indels 0; Gaps 0;				
LOCUS	QY 2151 TTGATTTTTTCCTCTTTTTTTTTTTTTTTTAACTTGAAGTT 2199				
DEFINITION					
LOCUS	Db 49 TTTT				
DEFINITION					
LOCUS	RESULT 4				
DEFINITION	LOCUS AI350847				
DEFINITION	AI350847 49 bp mRNA linear EST 30-DEC-1998				
LOCUS	qtl1e08.x1 NCI_CGAP-GC4 Homo sapiens cDNA clone IMAGE:1947302 3'				
DEFINITION	similar to gb:J05021 EZRIN (HUMAN);, mRNA sequence.				
LOCUS	AI350847				
DEFINITION	AI350847.1 GI:4088053				
LOCUS	KEYWORDS				
DEFINITION	EST.				
LOCUS	SOURCE				
DEFINITION	human.				
LOCUS	ORGANISM Homo sapiens				

SQL	Sequence	49 bp;	39 A;	0 C;	8 G;	2 T;	0 other;
Query Match	1.1%;	Score 31;	DB 2;	Length 49;			
Best Local Similarity	87.2%;	Pred. No. 1.5e+06;					
Matches	34;	Conservative	0;	Mismatches	5;	Indels	0;
OY	2151	TTGATTTTTTCTCCCTTTTTTTTTTTTTTTTAAAC	2189				
DB	46	TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAAC	8				
RESULT 11							
AI431439		49 bp	mrna	linear	EST 09-MAR-1999		
DEFINITION	AI431439	th36h10.x1 NCI CGAP Panl Homo sapiens cDNA clone IMAGE:2120419 3'					
ACCESSION	AI431439	similar to contains Alu repetitive element;;					
VERSION	AI431439.1	GI:4303194					
KEYWORDS	EST.						
SOURCE	human.						
ORGANISM	Homo sapiens						
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;						
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.						
TITLE	NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.						
JOURNAL	National Cancer Institute, Cancer Genome Anatomy Project (CGAP),						
COMMENT	Tumor Gene Index						
Unpublished (1997)	Contact: Robert Strausberg, Ph.D.						
Email: cgapbs@mail.nih.gov	Life Technologies catalog #:	11548-013					
DNA sequencing by: Washington University Genome Sequencing Center	Clone distribution: NCI-CGAP clone distribution information can be	found through the I.M.A.G.E. Consortium/ILML at:					
www-bio.lnl.gov/bhrp/imag/imag.html	Seq primer: -40up from G1bco.	Location/Qualifiers					
FEATURES	1. .49						
source	/organism="Homo sapiens"						
	/db_xref="taxon:9606"						
	/clone="IMAGE:2120419"						
	/clone_lib="NCI-CGAP_Panl"						
	/tissue_type="adenoocarcinoma"						
	/lab_host="DH10B"						
	/note="Organ: pancreas; Vector: PCMV-SpOrf6; Site_1: SalI;						
	Site_2: NotI; Cloned unidirectionally. Primer: Oligo dr.						
	Average insert size 1.72 kb. Life Technologies catalog #:						
	11548-013"						
BASE COUNT	4 a	0 c	1 g	44 t			
ORIGIN							
Query Match	1.1%;	Score 31;	DB 9;	Length 49;			
Best Local Similarity	78.7%;	Pred. No. 1.5e+06;					
Matches	37;	Conservative	0;	Mismatches	10;	Indels	0;
OY	2151	TTGATTTTTTCTCCCTTTTTTTTTTTTAACTTGAAG	2197				
DB	1	TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTATAG	47				
RESULT 12							
LOCUS	BF582680	45 bp	mrna	linear	EST 12-DEC-2000		
DEFINITION	602009408F1 NCL_CGAP_Co24 Mus musculus cDNA clone IMAGE:4208373 5'						
ACCESSION	BF582680						
VERSION	BF582680						
KEYWORDS	EST.						
SOURCE	house mouse.						
ORGANISM	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.						
REFERENCE	1 (bases 1 to 45)						

